Heart:房颤患者临床表现与1年预后的性别差异如何?

2017-02-23 xing.T MedSci原创

由此可见,女性房颤患者症状更多,但不太可能接受侵入性的节律控制治疗如心脏电复律或消融。需要进一步的研究来确认这些差异对女性房颤患者产生不利影响。

近日,在心脏病领域权威杂志Heart上发表了一篇研究文章,研究人员旨在评估房颤患者在临床表现、治疗和预后上的性别差异。

该研究纳入了6412例房颤患者,39.7%为女性,这些患者来自于血栓栓塞事件的预防-房颤欧洲注册中心,研究人员评估了房颤患者症状、危险因素、治疗和1年不良预后发生率的性别差异。

研究人员发现男性房颤患者整体要比女性房颤患者年轻(平均值±标准差:70.1±10.7岁 vs. 74.1±9.7岁,P<0.0001)。与男性相比,女性患者更频繁地出现至少一个房颤相关症状(女性为95.4%,男性为89.8%,P<0.0001)。两者口服抗凝药较为相似,服用非维生素K拮抗剂口服抗凝药的增加女性从5.9%到12.6%,男性从6.2%到12.6%,两者均有P<0.0001。

男性患者更常接受心脏电复律和消融治疗(分别为20.6%和6.3%),相比于女性(分别为14.9%和3.3%,P<0.0001)。1年后,女性发生经年龄调整和国家调整的冠状动脉血运重建几率要低65%(比值比为0.35;95%可信区间为0.22-0.56),急性冠脉综合征要低40%(比值比为0.60;0.38-0.93)和心衰要低20%(比值比为0.80;0.68-0.96)。1年卒中/短暂性脑缺血发作/动脉血栓栓塞和大出血事件的性别差异无统计学意义。

由此可见,女性房颤患者症状更多,但不太可能接受侵入性的节律控制治疗如心脏电复律或消融。需要进一步的研究来确认这些差异对女性房颤患者产生不利影响。

原始出处:

Renate B Schnabel,et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart. 2017. http://dx.doi.org/10.1136/heartjnl-2016-310406

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1356177, encodeId=650e13561e7da, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562443, encodeId=ae87156244393, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614341, encodeId=78d11614341b3, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177678, encodeId=85f11e7678b3, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Feb 24 06:26:56 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-25 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1356177, encodeId=650e13561e7da, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562443, encodeId=ae87156244393, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614341, encodeId=78d11614341b3, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177678, encodeId=85f11e7678b3, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Feb 24 06:26:56 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-25 slcumt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1356177, encodeId=650e13561e7da, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562443, encodeId=ae87156244393, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614341, encodeId=78d11614341b3, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177678, encodeId=85f11e7678b3, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Feb 24 06:26:56 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1356177, encodeId=650e13561e7da, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562443, encodeId=ae87156244393, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614341, encodeId=78d11614341b3, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Feb 25 08:51:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177678, encodeId=85f11e7678b3, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Feb 24 06:26:56 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-24 忠诚向上

    好好学习

    0

相关资讯

Stroke:女性房颤患者发生严重脑卒中的患者会更多吗?

相比于男性房颤患者,女性房颤患者不仅发生脑卒中的风险增加,而且更容易发生更加严重的脑卒中。

Eur Heart J:房颤消融术后患者的并发症评估

ESC-EHRA心房颤动消融长期注册是一项前瞻性的多国研究,旨在提供当代世界心房颤动(AFIB)消融的结果。近期,一项发表在Eur Heart J杂志上的文章评估了AFIB术后患者的生活现状。研究选取了27个欧洲国家共104个中心,登记20-50个患者首次进行并在此进行AFib消融。在网络电子病例记录表上记录了试验前、试验中及随后1年的随访数据。最后共有3630例患者,其中3593例接受AFib消

Eur Heart J:越来越多的房颤患者服用口服抗凝剂

自2010以来,丹麦更多的房颤事件患者为主的NOAC处方OAC治疗。增加的女性中,在中风的高风险的患者中,老年患者。

盘点:近期房颤相关研究学术成果一览

近年来,房颤的全球发病率逐年增高。目前我国已经成为房颤第一大国。房颤所致的脑卒中具有高致残率、高病死率及高复发率的特点。一旦发生房颤,可使脑卒中风险增加5倍。近期的一项JACC研究中,Chan等人分析了单独智能手机应用(APP)在基础医疗中的房颤筛查作用。Cardiio Rhythm智能手机应用可以确定RR间隔(然后是节律),其工作方式是使用者将一根手指置于智能手机相机上,再通过手机LED灯闪

Stroke:房颤患者卒中预防选择利伐沙班还是达比加群或华法林?

这个系统评价和荟萃分析显示,在房颤患者脑卒中/血栓栓塞预防上利伐沙班与达比加群一样有效,但比华法林更有效。利伐沙班与达比加群发生大出血的风险要显著增加,全因死亡率和胃肠道出血也一样。利伐沙班与华法林发生大出血风险类似,但胃肠道出血的风险增加而颅内出血风险降低。

Heart:达比加群对不同年龄的心房颤动患者疗效有啥影响?

在所有年龄组达比加群相比于华法林对卒中预防和颅内出血的效应是一致的。达比加群对颅外大出血的效应具有年龄依赖性,对于老年(≥80 年)患者,支持进行达比加群110毫克每日两次治疗。